Immune-related saliva micro-RNA’s to predict clinical response to a combination of cetuximab and low-dose chemotherapy in head and neck cancer (HNSCC) patients (pts) with poor performance status (PS).

A change in Medicare reimbursement for a prosthetic device that allows people who have had their voice box removed to speak has led some providers to stop offering the device or reducing the number of ...

Patients who lose their ability to speak after surgical treatment for throat cancer may be able to regain that ability much more quickly thanks to a new device developed by researchers at the National ...